Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal, and cellular immunity

Journal of Virology

Volumn 73, Issue 11, 1999, Pages 9485-9495

  Crotty, Shane ^a   Lohman, Barbara L ^b   Lü, Fabien X S ^b   Tang, Shenbei ^a   Miller, Christopher J ^b,c   Andino, Raul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIGEN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; GENE TARGETING; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE PROLIFERATION; MACACA; MOLECULAR CLONING; MUCOSAL IMMUNITY; NONHUMAN; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; SEROTYPE; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VACCINATION;

EID: 0032875716     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.11.9485-9495.1999     Document Type: Article

References (66)

1. Abbas, A. K., A. H. Lichlman, and J. S. Pober. 1997. Cellular and molecular immunology, 3rd ed. W. B. Saunders, Philadelphia, Pa.
2. American Hospital Formulary Service. 1998. AFHS drug information. American Society of Hospital Pharmacists, SilverPlatter International, Bethesda, Md.
3. Andino, R., G. E. Rieckhof, P. L. Achacoso, and D. Baltimore. 1993. Poliovirus RNA synthesis utilizes an RNP complex formed around the 5′-end of viral RNA. EMBO J. 12:3587-3598.
4. Andino, R., D. Silvera, S. D. Suggett, P. L. Achacoso, C. J. Miller, D. Baltimore, and M. B. Feinberg. 1994. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science 265:1448-1451.
5. Barnett, S. W., J. M. Klinger, B. Doe, C M. Walker, L. Hansen, A. M. Duliège, and F. M. Sinangil. 1998. Prime-boost immunization strategies against HIV. AIDS Res. Hum. Retroviruses 14(Suppl. 3):S299-S309.
6. Benson, J., C. Chougnet, M. Robert-Guroff, D. Monteflori, P. Markham, G. Shearer, R C. Gallo, M. Cranage, E. Paoletti, K. Limbach, D. Venzon, J. Tartaglia, and G. Franchlni. 1998. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J. Virol. 72:4170-4182.
7. Buge, S. L., E. Richardson, S. Alipanah, P. Markham, S. Cheng, M. Kalyan, C. J. Miller, M. Lubeck, S. Udem, J. Eldridge, and M. Robert-Guroff. 1997. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreased viral burden following vaginal challenge. J. Virol. 71:8531-8541.
8. Crotty, S., S. Mandl, and R. Andino. Unpublished data.
9. Dove, A. W., and V. R. Racaniello. 1997. The polio eradication effort: should vaccine eradication be next? Science 277:779-780.
10. Faber, H-, and R. Silverberg. 1941. Experimental airborne infection with poliomyelitis virus. Science 94:566-568.
11. Faber, H. K. 1955. The pathogenesis of poliomyelitis, 1st ed. Charles C. Thomas, Springfield, Ill.
12. Faber, H. K., R. J. Silverberg, and L. Dong. 1948. Poliomyelitis in Philippine cynomolgus monkeys after simple feeding. Am. J. Hyg. 48:94-98.
13. Faber, H. K., R. J. Silverberg, and L. Dong. 1944. Poliomyelitis in the cynomolgus monkey. III. Infection by inhalation of droplet nuclei and the nasopharyngeal portal of entry, with a note on this mode of infection in rhesus. J. Exp. Med. 80:39-57.
14. Faden, H., J. Modlin, M. L. Thorns, A. M. McBean, M. B. Ferdon, and P. L. Ogra. 1990. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J. Infect. Dis. 162:1291-1297.
15. Graham, S., E. C. Wang, O. Jenkins, and L. K. Borysiewicz. 1993. Analysis of the human T-cell response to picornaviruses: identification of T-cell epitopes close to B-cell epitopes in poliovirus. J. Virol. 67:1627-1637.
16. Gromeier, M., B. Bessert, M. Arita, A. Nomoto, and E. Wimmer. 1999. Dual stem loops within the poliovirus internal ribcsomal entry site control neurovirulence. J. Virol. 73:958-964.
17. Howe, H. A., and D. Bodian. 1948. Poliomyelitis in the cynomolgus monkey following oral inoculation. Am. J. Hyg. 48:99-106.
18. Huber, S. A., L. P. Job, and J. F. Woodruff. 1980. Lysis of infected myofibers by coxsackie B3-immune T lymphocytes. Am. J. Pathol. 98:681-694.
19. Hull, H. F, and R. B. Aylward. 1997. Ending polio immunization. Science 277:780.
20. Hull, H. F., N. A. Ward, B. P. Hull, J. B. Milstien, and C. de Quadros. 1994. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 343:1331-1337.
21. Iizuka, N., M. Kohara, K. Hagino-Yamagishi, S. Abe, T. Komatsu, K. Tago, M. Arita, and A. Nomoto. 1989. Construction of less neurovirulent polioviruses by introducing deletions into the 5′ noncoding sequence of the genome. J. Virol. 63:5354-5363.
22. Imaoka, K., C. J. Miller, M. Kubota, M. B. McCbesney, B. Lohman, M. Yamamoto, K. Fugihashi, K. Someya, M. Honda, J. R. McGhee, and H. Kiyono. 1998. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus specific immune responses in reproductive tissues. J. Immunol. 161:5952-5958.
23. Kestler, H., T. Kodama, D. Ringler, M. Marthas, N. Pedersen, A. Lackner, D. Regier, P. Sehgal, M. Daniel, N. King, and R. Desrosiers. 1990. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248:1109-1112.
24. Lehner, T., Y. Wang, M. Cranage, L. A. Bergmeier, E. Mitchell, L. Tao, G. Hall, M. Dennis, N. Cook, R. Brookes, L. Klavinskis, I. Jones, C. Doyle, and R. Ward. 1996. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat. Med. Med. 2:767-775.
25. Lepow, M. L., R. J. Warren, N. Gray, V. G. Ingram, and F. C. Robbins. 1961. Effect of Sabin type 1 poliomyelitis vaccine administered by mouth to new-born infants. N. Engl. J. Med. 264:1071-1078.
26. Lohman, B. L., M. B. McChesney, C. J. Miller, E. McGowan, S. M. Joye, K. K. Van Rompay, E. Reay, L. Antipa, N. C. Pedersen, and M. L. Marthas. 1994. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68:7021-7029.
27. Lohman, B. L., C. J. Miller, and M. B. McChesney. 1995. Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. J. Immunol. 155:5855-5860.
28. Lü, X., H. Kiyono, D. Lu, S. Kawabata, J. Torten, S. Srinivasan, P. J. Dailey, J. R. McGhee, T. Lehner, and C. J. Miller. 1997. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251. AIDS 12:1-10.
29. Mahon, B. P., K. Katrak, A. Nomoto, A. J. Macadam, P. D. Minor, and K. H. Mills. 1995. Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. J. Exp. Med. 181:1285-1292.
30. Mandl, S., L. J. Sigal, K. L. Rock, and R. Andino. 1998. Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proc. Natl. Acad. Sci. USA 95:8216-8221.
31. Mastro, T. D., and D. Kitayaporn. 1998. HIV type 1 transmission probabilities: estimates from epidemiological studies. AIDS Res. Hum. Retroviruses 14(Suppl. 3):S223-S227.
32. McAllister, A., A. Arbetman, S. Mandl, and R. Andino. Unpublished data.
33. +-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV. J. Virol. 72:10029-10035.
34. Melnick, J. L. 1996. Enteroviruses: polioviruses, coxsackieviruses, echoviruses. and newer enteroviruses, p. 655-712. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.). Fields virology, 3rd ed., vol. 1. Lippincott-Raven Publishers, Philadelphia, Pa.
35. Miller, C. J., M. Marthas, J. Torten, N. J. Alexander, J. P. Moore, G. F. Doncel, and A. G. Hendrickx. 1994. Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J. Virol. 68:6391-6400.
36. Miller, C. J., M. B. McChesney, X. Lu, P. J. Dailey, C. Chutkowski, D. Lu, P. Brosio, B. Roberts, and Y. Lu. 1997. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J. Virol. 71:1911-1921.
37. Mills, K. H. G., P. A. Kitchin, B.P. Mahon, A. L. Barnard, S. E. Adams, S. M. Kingsman, and A. J. Kingsman. 1990. HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1. J. Immunol. 144:1677-1683.
38. Minor, P. D. 1997. Poliovirus, p. 555-574. In N. Nathanson and R. Ahmed (ed.), Viral pathogenesis. Lippincott-Raven, Philadelphia, Pa.
39. Morrow, C. D., D. C. Porter, D. C, Ansardi, Z. Moldoveanu, and P. N. Fultz. 1994. New approaches for mucosal vaccines for AIDS: encapsidation and serial passages of poliovirus replicons that express HIV-1 proteins on infection. AIDS Res. Hum. Retroviruses 10(Suppl. 2):S61-S66.
40. Mueller, S., and E. Wimmer. 1998. Expression of foreign proteins by poliovirus polyprotein fusion: analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames. J. Virol. 72:20-31.
41. Nilsson, C., B. Mäkitalo, R. Thorstensson, S. Norley, D. Binninger-Schinzel, M. Cranage, E. Rud, G. Biberfeld, and P. Putkonen. 1998. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12:2261-2270.
42. Ogra, P. L. 1999. Mucosal immunology, 2nd ed. Academic Press, San Diego, Calif.
43. Ogra, P. L., M. Fishaut, and M. R. Gallagher. 1980. Viral vaccination via the mucosal routes. Rev. Infect. Dis. 2:352-369.
44. Ogra, P. L., and D. T. Karon. 1971. Formation and function of poliovirus antibody in different tissues. Prog. Med. Virol. 13:156-193.
45. Ogra, P. L., and D. T. Karzon. 1969. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J. Immunol. 102:1423-1430.
46. Ogra, P. L., and D. T. Karzon. 1969. Poliovirus antibody response in serum and nasal secretions following intranasal inoculation with inactivated poliovaccine. J. Immunol. 102:15-23.
47. Ogra, P. L., and S. S. Ogra. 1973. Local antibody response to poliovaccine in the human female genital tract. J. Immunol. 110:1307-1311.
48. Paul, J. R., J. T. Riordan, and J. L. Melnick. 1951. Antibodies to three different antigenic types of poliomyelitis virus in sera from north Alaskan Eskimos. Am. J. Hyg. 54:275-285.
49. Plotkin, S., and W. Orenstein (ed.). 1999. Vaccines, 3rd ed. W. B. Saunders Company, Philadelphia, Pa.
50. Ren, R. B., F. Costantini, E. J. Gorgacz, J. J. Lee, and V. R. Racaniello. 1990. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 63:353-362.
51. Rossi, C. P., A. McAllister, M. Tanguy, D. Kägi, and M. Brahic. 1998. Theiler's virus infection of perforin-deficient mice. J. Virol. 72:4515-4519.
52. Royce, R. A., A. Sena, W. Cates, Jr., and M. S. Cohen. 1997. Sexual transmission of HIV. N. Engl. J. Med. 336:1072-1078.
53. Sabin, A. B. 1956. Pathogenesis of poliomyelitis. Science 123:1151-1157.
54. Sabin, A. B. 1959. Present position of immunization against poliomyelitis with live virus vaccines. Br. Med. J. 1:663-680.
55. Savilahti, E., T. Klemola, B. Carlsson, L. Mellander, M. Stenvik, and T. Hovi. 1988. Inadequacy of mucosal IgM antibodies in selective IgA deficiency: excretion of attenuated poliovirus is prolonged. J. Clin. Immunol. 8:89-94.
56. Schultz, A. 1998. Encouraging vaccine results from primate models of HIV type 1 infection. AIDS Res. Hum. Retroviruses 14(Suppl. 3):S261-S263.
57. Schultz, A. 1998. Using recombinant vectors as HIV vaccines. IAVI Rep. 3:1-4.
58. Sigal, L. J., S. Crotty, R. Andino, and K. L. Rock. 1999. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398:77-80.
59. Simons, J., M. Kutubuddin, and M. Chow. 1993. Characterization of poliovirus-specific T lymphocytes in the peripheral blood of Sabin-vaccinated humans. J. Virol. 67:1262-1268.
60. Smith, A. D., S. C. Geisler, A. A. Chen, D. A Resnick, B. M. Roy, P. J. Lewi, E. Arnold, and G. F. Arnold. 1998. Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1. J. Virol. 72:651-659.
61. Smith, J. W., J. A. Lee, W. B. Fletcher, C. A. Morris, D. A. Parker, R. Yetts, D. I. Magrathe, and F. T. Perkins. 1976. The response to oral poliovaccine in persons aged 16-18 years. J. Hyg. 76:235-247.
62. Sutter, R. W., S. L. Cochi, and J. L. Melnick. 1999. Live attenuated poliovirus vaccines, p. 1230. In S. Plotkin and W. Orenstein (ed.), Vaccines, 3rd ed. W. B. Saunders, Philadelphia, Pa.
63. Tang, S., R. van Rij, D. Silvera, and R. Andino. 1997. Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity. J. Virol. 71:7841-7850.
64. UNAIDS and the World Health Organization. 1998. Report on the global HIV/AIDS epidemic. World Health Organization, Geneva, Switzerland.
65. Vallbracht, A., Y. Maier, D. Stierhof, K. H. Wiedmann. B. Flehmig, and B. Fleischer. 1989. Liver-derived cytotoxic T cells in hepatitis A virus infection. J. Infect. Dis. 160:209-217.
66. Van der Ryst, E., T. Nakasone, A. Habel, A. Venet, E. Gomard, R. Altmeyer, M. Girard, and A. M. Borman. 1998. Study of the immunogenicity of different recombinant Mengo viruses expressing HIV1 and SIV epitopes. Res. Virol. 149:5-20.